These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3419558)

  • 1. Cholecystokinin and an evoked response in the dentate gyrus.
    Sinton CM
    Neuropeptides; 1988 Jul; 12(1):29-34. PubMed ID: 3419558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin and cholecystokinin antagonists enhance postsynaptic excitability in the dentate gyrus.
    Sinton CM
    Peptides; 1988; 9(5):1049-53. PubMed ID: 3244557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin modulates neurotransmission through the dentate gyrus.
    Sinton CM
    Neurosci Lett; 1988 Dec; 95(1-3):341-6. PubMed ID: 2852324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemically administered cholecystokinin affects an evoked potential in the hippocampal dentate gyrus.
    Dahl D
    Neuropeptides; 1987; 10(2):165-73. PubMed ID: 3683771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central administration of cholecystokinin potentiates evoked potential amplitude in the hippocampal dentate gyrus.
    Dahl D
    Neuropeptides; 1988; 11(4):147-51. PubMed ID: 3419554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice.
    Suh HH; Tseng LF
    Eur J Pharmacol; 1990 Apr; 179(3):329-38. PubMed ID: 2142090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking of cholecystokinin octapeptide behavioral effects by proglumide.
    Katsuura G; Hsiao S; Itoh S
    Peptides; 1984; 5(3):529-34. PubMed ID: 6089145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of synaptic transmission in the hippocampus by cholecystokinin (CCK) and its antagonism by a CCK analog (CCK27-33).
    MacVicar BA; Kerrin JP; Davison JS
    Brain Res; 1987 Mar; 406(1-2):130-5. PubMed ID: 3032354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cholecystokinin on acetylcholine turnover and dopamine release in the rat striatum and cortex.
    Cosi C; Altar AC; Wood PL
    Eur J Pharmacol; 1989 Jun; 165(2-3):209-14. PubMed ID: 2776829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebroventricular injections of cholecystokinin octapeptide suppress feeding in rats--pharmacological characterization of this action.
    Schick RR; Yaksh TL; Go VL
    Regul Pept; 1986 Jul; 14(4):277-91. PubMed ID: 3749526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of cholecystokinin antagonists on satiety induced by cholecystokinin octapeptide in dogs].
    Sakatani N; Inui A; Baba S
    Nihon Naibunpi Gakkai Zasshi; 1989 Oct; 65(10):1149-58. PubMed ID: 2591604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin-octapeptide restored morphine-induced hippocampal long-term potentiation impairment in rats.
    Wen D; Zang G; Sun D; Yu F; Mei D; Ma C; Cong B
    Neurosci Lett; 2014 Jan; 559():76-81. PubMed ID: 24309294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of cholecystokinin and cholecystokinin antagonists on synaptic function in the CA1 region of the rat hippocampal slice.
    Jaffe DB; Aitken PG; Nadler JV
    Brain Res; 1987 Jul; 415(1):197-203. PubMed ID: 3040174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unsulfated CCK-8 not blocked by proglumide or CR 1409 in the mouse abdominal irritant-induced stretching assay: possible central site of action.
    Ambrose FG; Barbaz BS; Autry WL; Browne RG; Liebman JM
    Peptides; 1989; 10(1):31-4. PubMed ID: 2748423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
    Altar CA; Boyar WC
    Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin receptor subtypes and neuromodulation.
    Altar CA
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):381-93. PubMed ID: 2748871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of climbing and mossy fiber input to mouse cerebellar Purkinje cells by cholecystokinin.
    Wood PL; Steel DJ; Kim HS; Petrack B; Altar CA
    J Pharmacol Exp Ther; 1988 Jan; 244(1):58-62. PubMed ID: 2826774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intracerebroventricular administration of two molecular forms of sulfated CCK octapeptide on anxiety-like behavior in the zebrafish danio rerio.
    Matsuda K; Yoshida D; Sachuriga ; Watanabe K; Yokobori E; Konno N; Nakamachi T
    Peptides; 2020 Aug; 130():170330. PubMed ID: 32445877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin and its antagonist lorglumide respectively attenuate and facilitate morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurons.
    Kellstein DE; Price DD; Mayer DJ
    Brain Res; 1991 Feb; 540(1-2):302-6. PubMed ID: 2054623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proglumide has access to brain and antagonizes the central satiety effect of cholecystokinin octapeptide in the dog.
    Inui A; Inoue T; Sakatani N; Oya M; Morioka H; Baba S
    Brain Res; 1987 Aug; 417(2):355-9. PubMed ID: 3651819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.